News

Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer.

Don't let anyone tell you that you must have a boatload of money to get started investing in stocks. It's simply not true. Sure, you'll need some upfront cash. However, even a modest amount is

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Viatris (NASDAQ: VTRS) hasn't made for a particularly great investment since it formed nearly three years ago, through a merger of Mylan and Pfizer's Upjohn business. Down 29% since then, it has

Novavax (NASDAQ: NVAX) has gone from a pandemic darling to a bust, with its shares falling by a whopping 83% over the past 12 months. The hope and optimism surrounding the stock has faded. Earlier

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Being a buy-and-hold investor has advantages. For instance, it can be less stressful than day trading, and the combination of time and compounding is a powerful wealth generator. However, with

Pharma giant AbbVie (NYSE: ABBV) performed poorly in the first part of the year, especially after it reported its first-quarter results. This was its first quarterly update following the loss of

Canada's Tilray Brands (NASDAQ: TLRY) is having a strong trading session today. Specifically, the consumer packaged goods and cannabis company's stock was up by 6.75% on heavy volume as of 1:31 p.m

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

Viatris (NASDAQ: VTRS) could be on the verge of eating the lunch of Novo Nordisk's (NYSE: NVO) two golden cash cows: The diabetes drug Ozempic, and another version that's formulated for weight loss

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

Healthcare company Amgen (NASDAQ: AMGN) has been a reliable investment to own over what has been a turbulent year for the broader market. Its stock price is up 6.6% in that time, outpacing the 3.2%

When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend. Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest

When a company's revenue and earnings plunge, it's understandable if investors begin to worry about its dividend. Pfizer (NYSE: PFE) reported a 53% year-over-year decline in revenue in its latest

If you are looking for reliable dividend stocks that can provide steady income and growth in any market condition, you might want to consider these two blue chip companies that have proven their

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys

High-yield dividend stocks often deliver better-than-average returns for investors over the long term, thanks to the power of compounding. Not all high-yield dividend stocks are table-pounding buys